Shahin Jamal
Overview
Explore the profile of Shahin Jamal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
720
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ladouceur A, Jamal S, Saltman A, Himmel M, Hudson M, Pope J, et al.
ACR Open Rheumatol
. 2025 Feb;
7(2):e70002.
PMID: 39964344
Objective: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) and progression-free survival (PFS) in many types of malignancies but can result in off-target immune-related adverse events including inflammatory arthritis (ICI-associated...
2.
Roberts J, Jamal S, Hudson M, Katz S, Ennis D, Maltez N, et al.
Musculoskeletal Care
. 2025 Feb;
23(1):e70065.
PMID: 39947713
No abstract available.
3.
Li J, Li J, Hudson M, Ye C, Roberts J, Fifi-Mah A, et al.
J Rheumatol
. 2024 Dec;
PMID: 39681372
Objective: Immune checkpoint inhibitors (ICIs) have revolutionized cancer outcomes but are limited by immune-related adverse events (irAEs), including rheumatic irAEs (Rh-irAEs). Aging is associated with increased inflammation, referred to as...
4.
Nikolic R, Pardo J, Pope J, Barber C, Barnabe C, Schieir O, et al.
J Rheumatol
. 2024 Jul;
51(9):940-941.
PMID: 39009382
No abstract available.
5.
Johnson D, Jamal S, Hung R, Ye C
J Immunother
. 2024 May;
47(7):275-278.
PMID: 38764383
Fluorine-18 fluorodeoxygluocose positron emission tomography (FDG-PET) is increasingly used in the evaluation of response to immune checkpoint inhibitor (ICI) therapy. Incidental findings of increased vessel wall uptake may prompt the...
6.
Cho L, Jamal S
Rheum Dis Clin North Am
. 2024 Apr;
50(2):301-312.
PMID: 38670728
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment through blocking immunoregulatory pathways, resulting in augmented antitumor responses. However, ICIs can cause inflammatory autoimmune toxicities, known as immune-related adverse events (irAEs)....
7.
Ladouceur A, Ezdoglian A, Sparks J, Hudson M, Jamal S, Clifford A, et al.
Rheum Dis Clin North Am
. 2024 Apr;
50(2):181-199.
PMID: 38670720
Immune checkpoint inhibitors (ICIs) have greatly improved survival of several cancers with historically very poor prognosis. ICIs act by stimulating the patient's own immune system to fight cancer. Simultaneously, this...
8.
Rouhi A, Jamal S, Arreola L, Moon D, Hudson M, Roberts J, et al.
J Rheumatol
. 2024 Mar;
51(5):523-528.
PMID: 38428960
Objective: Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is characterized by symmetrical synovitis with pitting edema and negative rheumatoid factor (RF). It has been described in a setting of...
9.
Hazlewood G, Akhavan P, Pardo J, Agarwal A, Schieir O, Barber C, et al.
J Rheumatol
. 2023 Aug;
50(9):1198-1199.
PMID: 37527865
No abstract available.
10.
Ghosh N, Couette N, van Binsbergen W, Weinmann S, Jivanelli B, Shea B, et al.
Semin Arthritis Rheum
. 2022 Nov;
58:152110.
PMID: 36372016
Introduction: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR)....